One of such trials (NCT05079022) aims to assess the role of Furmonertinib, a third generation anti-EGFR, in EGFR-mutated radically resected stage I lung cancers, with the mutation being detected trough ctDNA analysis. The gene discussed is EGFR; the disease is lung cancer.